A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma
试验速览
- 阶段
- 2 期
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- R0 Resection Rate
研究概览
简要总结
Within the next decade, pancreatic ductal adenocarcinoma (PDAC) is expected to rise to the second leading cause of cancer-related mortality. To increase the survival, various peri-operative treatments have been tested, and adjuvant FOLFIRINOX or gemcitabine plus capecitabine is now standard of care after surgical resection for localized PDAC. Even with superior survival among various disease extent of PDAC, resectable PDAC still shows poor outcomes with surgery followed by adjuvant chemotherapy. This phase II study is investigating the role of modified-FOLFIRINOX as neoadjuvant treatment for resectable PDAC.
详细描述
This phase II study is designed to evaluate the efficacy and safety of modified FOLFIRINOX as neoadjuvant treatment for resectable pancreatic cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with pancreatic ductal adenocarcinoma confirmed by histological or cytopathological examination
- •Pancreatic adenocarcinoma patients evaluated as resectable according to the following criteria in imaging tests including CT or MRI (NCCN guideline criteria, if all of the following criteria are satisfied) A. No tumor contact with the major arterial structures of the Celiac axis [CA], superior mesenteric artery [SMA], and common hepatic artery [CHA].
- •B. When there is no contact between the tumor and the major vein of the superior mesenteric vein (SMV) or portal vein (PV), or within 180° even if there is contact, and there is no venous atypicality.
- •Patients who have not undergone surgical resection and systemic chemotherapy for pancreatic cancer.
- •Patients whose ECOG activity ability index is 0 to 1
- •Patients who are willing and able to provide written informed consent for this study.
- •Patients over the age of 19 at the time of signing the subject consent form.
- •Patients with evaluable lesions according to RECIST 1.
- •Patients with adequate organ function.
排除标准
- •Histologic diagnosis other than pancreatic ductal adenocarcinoma (eg, neuroendocrine tumor, etc.)
- •Patients with distant metastases including central nervous system (CNS) metastases or peritoneal metastases
- •Patients with moderate acute or chronic medical conditions or abnormal findings on examination, which are judged to affect the results of this study
- •Patients who have participated in a study in which investigational drugs are used and are currently receiving investigational drugs or used investigational drugs or medical devices within 4 weeks prior to the first administration of this investigational drug.
- •Those who received chemotherapy, targeted small molecule agents, or radiotherapy within 2 weeks prior to Day 1 of the study, or who have not yet recovered (Grade 1 or lower or baseline level) from adverse reactions due to previously administered drugs patient.
- •Patients with known aggravation within the past 3 years or other malignant tumors requiring active treatment.
研究组 & 干预措施
modified FOLFIRINOX
oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,000 mg/m2 42~46h continuous infusion, every other week for 6 cycles (12 weeks).
干预措施: neoadjuvant modified FOLFIRINOX (Drug)
结局指标
主要结局
R0 Resection Rate
时间窗: Post surgery (within one week)
R0 resection rate with pathology report after curative aim surgery.
次要结局
- Objective response rate(3 months)
- overall survival(up to 2 years)
- disease-free survival(up to 2 years)
- Progression Free Survival(up to 2 years)